• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
World Diabetes Market Analysis 2010-2025
 

World Diabetes Market Analysis 2010-2025

on

  • 218 views

How will the diabetes market develop, with rising disease prevalence in many countries'In 2009, the diabetes treatment market generated worldwide sales of over $25 billion, with strong growth from the ...

How will the diabetes market develop, with rising disease prevalence in many countries'In 2009, the diabetes treatment market generated worldwide sales of over $25 billion, with strong growth from the previous year. The incidence and prevalence of diabetes mellitus are on the rise worldwide, in line with lifestyle changes and ageing populations. In particular, the increasing prevalence of diabetes is closely linked with that of obesity, creating significant market opportunities in developed nations and some developing countries. The World Health Organization estimates the number of diabetics to exceed 350 million by 2030. Governments and other healthcare providers around the world are investing heavily in prevention and treatment of this serious - but controllable - disorder.As our new report ' World Diabetes Market Analysis 2010-2025 ' shows, the diabetes market is one of the most important sectors in the pharmaceutical industry. All segments of the diabetes therapy market have been expanding, but which will grow fastest in years to come' What are the main therapeutic and commercial trends to watch' How will the principal national markets perform from 2010 to 2025' What will happen to the current leading products/therapies' How does diabetes overlap with obesity' This report covers those and other crucial questions, providing the information that you need.Success in the diabetes treatment market from 2010 onwards will be characterised by the launch of products with superior performance. This report shows how emerging technologies that increase clinical effectiveness, tolerability and ease of use will be important therapeutically and commercially.Detailed analysis of the global diabetes marketWorld Diabetes Market Analysis 2010-2025 examines that sector through a comprehensive review of information sources. We harness both primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of R&D pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 75 tables and figures included, as well as three full interviews with relevant authorities. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.Why you should buy World Diabetes Market Analysis 2010-2025This report gives you the following benefits in particular:' You will receive a comprehensive analysis of the prospects for anti-diabetes drugs from 2010 to 2025, including predicted revenues, growth rates and other metrics for leading products' You will receive an overall forecast for the global diabetes treatment market from 2010 to 2025, as well as those for main drug classes, with comprehensive discussions and other supporting information' You will find out where the market is heading ' both technologically and commercially ' from 2010 onwards' You will receive sales forecasts for the leading national markets from 2010 to 2025 (US, Japan, UK, Germany, France, Spain, Italy, Brazil, China and India)' You will identify key R&D pipeline developments and up-and-coming products' You will discover the drivers, restraints, competition and opportunities influencing the diabetic treatment sector, including insulins and oral anti-diabetics classes' You will investigate under-met needs in that sector, with both therapeutic requirements and commercial opportunities discussed' You will discover expert views from our survey, including full interview transcripts.' You can obtain this report todayThis report is essential reading for everybody interested in the diabetes treatments sector. With rising disease prevalence, expanding patient populations and unmet needs, this therapeutic area holds significant potential for further revenue growth. Our new study reveals prospects for both existing competitors and potential market entrants from the present onwards. You can stay ahead by ordering this report today.

Statistics

Views

Total Views
218
Views on SlideShare
218
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    World Diabetes Market Analysis 2010-2025 World Diabetes Market Analysis 2010-2025 Document Transcript

    • Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!World Diabetes Market Analysis 2010-2025Published on March 2010 Report SummaryHow will the diabetes market develop, with rising disease prevalence in many countriesIn 2009, the diabetes treatment market generated worldwide sales of over $25 billion, with strong growth from the previous year. Theincidence and prevalence of diabetes mellitus are on the rise worldwide, in line with lifestyle changes and ageing populations. Inparticular, the increasing prevalence of diabetes is closely linked with that of obesity, creating significant market opportunities indeveloped nations and some developing countries. The World Health Organization estimates the number of diabetics to exceed 350million by 2030. Governments and other healthcare providers around the world are investing heavily in prevention and treatment ofthis serious - but controllable - disorder.As our new report World Diabetes Market Analysis 2010-2025 shows, the diabetes market is one of the most important sectors inthe pharmaceutical industry. All segments of the diabetes therapy market have been expanding, but which will grow fastest in years tocome What are the main therapeutic and commercial trends to watch How will the principal national markets perform from 2010 to2025 What will happen to the current leading products/therapies How does diabetes overlap with obesity This report covers thoseand other crucial questions, providing the information that you need.Success in the diabetes treatment market from 2010 onwards will be characterised by the launch of products with superiorperformance. This report shows how emerging technologies that increase clinical effectiveness, tolerability and ease of use will beimportant therapeutically and commercially.Detailed analysis of the global diabetes marketWorld Diabetes Market Analysis 2010-2025 examines that sector through a comprehensive review of information sources. Weharness both primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions ofR&D pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 75 tablesand figures included, as well as three full interviews with relevant authorities. The result is a comprehensive market- andindustry-centred study, with detailed analyses and informed opinion to benefit your work.Why you should buy World Diabetes Market Analysis 2010-2025This report gives you the following benefits in particular: You will receive a comprehensive analysis of the prospects for anti-diabetes drugs from 2010 to 2025, including predicted revenues,growth rates and other metrics for leading products You will receive an overall forecast for the global diabetes treatment market from 2010 to 2025, as well as those for main drugclasses, with comprehensive discussions and other supporting information You will find out where the market is heading both technologically and commercially from 2010 onwards You will receive sales forecasts for the leading national markets from 2010 to 2025 (US, Japan, UK, Germany, France, Spain, Italy,Brazil, China and India) You will identify key R&D pipeline developments and up-and-coming products You will discover the drivers, restraints, competition and opportunities influencing the diabetic treatment sector, including insulins andoral anti-diabetics classesWorld Diabetes Market Analysis 2010-2025 Page 1/12
    • Find Industry reports, Company profilesReportLinker and Market Statistics You will investigate under-met needs in that sector, with both therapeutic requirements and commercial opportunities discussed You will discover expert views from our survey, including full interview transcripts. You can obtain this report todayThis report is essential reading for everybody interested in the diabetes treatments sector. With rising disease prevalence, expandingpatient populations and unmet needs, this therapeutic area holds significant potential for further revenue growth. Our new studyreveals prospects for both existing competitors and potential market entrants from the present onwards. You can stay ahead byordering this report today. Table of ContentTable of Contents1. Executive Summary1.1 The Diabetes Market Trajectory1.1.1 Visiongains Prediction for Total Diabetes Sales in 20251.1.2 Diabetes is Spreading at an Epidemic Rate: The Need for Pharmaceuticals is Growing1.1.3 Diabetes Care Works: The Market will Expand Significantly1.1.4 Awareness, Advocacy and Government Spending Aimed at Diabetes are all Expanding1.2 Aims, Scope and Format of the Report1.3 Research and Analysis Methods2. Introduction to Diabetes and its Treatment2.1 What is Diabetes Mellitus2.1.1 Symptoms of Diabetes2.1.2 Type 1 Diabetes2.1.3 Type 2 Diabetes2.1.4 Gestational Diabetes2.1.5 Other Types of Diabetes2.1.6 "Pre-Diabetes": Impaired Glucose Tolerance (IGT) and Metabolic Syndrome2.2 Health Consequences: Diabetes Can Cause Heart, Kidney, Eye, and Nerve Damage2.2.1 Heart Problems2.2.2 Kidney Damage2.2.3 Blindness2.2.4 Neuropathy2.2.5 Amputation2.2.6 Ketoacidosis, Coma, and Death2.3 Obesity: The Major Diabetes Risk Factor2.4 Other Risk Factors: Age, Genetics, Race2.4.1 Type 2 Diabetes Risk Increases with Age2.4.2 Obesity Increases Chances of Type 2 Diabetes2.4.3 Genetic Factors2.4.4 Type 1 Diabetes: Genetics vs. Environment2.4.5 Family History2.4.6 EthnicityWorld Diabetes Market Analysis 2010-2025 Page 2/12
    • Find Industry reports, Company profilesReportLinker and Market Statistics2.5 Diagnosis: Guidelines are Subject to Change2.6 Prevalence: Diabetes Rates are Rising Epidemically2.7 The Economic Costs of Diabetes: $58 billion in the US2.8 Treatments2.8.1 Insulin: a Central Therapeutic Product2.8.2 Medications2.8.3 More Novel Therapies A New Discovery about how Insulin Works May Lead to New Drugs2.9 Diabetes Treatment Noncompliance Rates 25% to 90%3. The World Diabetes Drug Market, 2010-20253.1 The World Diabetes Drug Market in 20093.1.1 Human Insulins & Analogues had Largest Market Share in 20093.1.2 Top Twenty Anti-Diabetic Brands, 20093.2 The World Diabetes Drug Market Forecast, 2010-20253.3 Anti-Diabetic Pharmaceutical Therapeutic Category Sales Forecasts, 2010-20253.3.1 Two Therapeutic Categories will Power Growth from 2010-20163.3.2 Human Insulins and Analogues will Continue to Drive Growth from 2017-20254. Human Insulins and Analogues: Market Prospects, 2010-20254.1 Leading Human Insulins and Analogues4.1.1 Lantus Commercial Prospects4.1.2 Novorapid Commercial Prospects4.1.3 Humalog Commercial Prospects4.1.4 Novomix Commercial Prospects4.1.5 Levemir Commercial Prospects4.1.6 Actraphane HM Commercial Prospects5. Other Anti-Diabetic Agents: Market Prospects, 2010-20255.1 Leading Oral Anti-Diabetic Products5.1.1 Actos Commercial Prospects5.1.2 Avandia: How will Sales Fare After 20135.1.3 Avandamet Commercial Prospects5.1.4 Januvia Commercial Prospects5.2 Byetta/Exenatide LAR: Potentially Revolutionary Non-Insulin Injection Blockbuster5.2.1 Byettas Strengths5.2.2 Restraints on Byetta6. Drivers and Restraints in the Diabetes Drug Market6.1 Strengths: Diabetes is Increasing, and Diabetes Drugs Work6.1.1 Diabetes is Chronic6.1.2 Younger Patients, More-Comprehensive Diagnoses6.1.3 Prevention is Inadequate6.1.4 Drugs Often Used in Combination6.2 Weaknesses6.2.1 Diagnostic Inadequacies6.2.2 Developing Countries Cannot Afford Many Drugs6.2.3 Noncompliance Rates up to 65%6.3 Opportunities6.3.1 Increasing Prevalence of Diabetes and Unhealthy Lifestyles6.3.2 The Greying of the World PopulationWorld Diabetes Market Analysis 2010-2025 Page 3/12
    • Find Industry reports, Company profilesReportLinker and Market Statistics6.3.3 Obesity: A Major Contributing Factor for Type 2 Diabetes6.3.4 Expanding Markets: India and China6.3.5 Changing Guidelines for Defining Diabetes6.3.6 Techniques for Increasing Patient Compliance6.3.7 Novel Drugs, Novel Delivery Methods6.4 Threats6.4.1 The Most-Significant Threat: Changes in Drug Approval Guidelines6.4.2 Changing FDA Guidelines for New Drug Approvals6.4.3 Generic Erosion of Branded Drug Sales6.4.4 Vaccine to Prevent Type 1 Diabetes6.4.5 Diabetes Drugs Side Effects7. Antidiabetic Drugs: Leading Country Markets, 2010-20257.1 Leading Anti-Diabetic Pharmaceutical Country Markets, 20097.2 Leading Developed Country Anti-Diabetic Pharmaceutical Markets, 2010-20257.2.1 The US Anti-Diabetic Pharmaceutical Market7.2.2 The Japanese Anti-Diabetic Pharmaceutical Market7.2.3 European Diabetes Pharmaceutical Markets7.3 Emerging Economy Anti-Diabetic Pharmaceutical Market Forecasts, 2010-20257.3.1 Anti-Diabetic Pharmaceuticals are Making the Leap to Developing Countries7.3.2 The Chinese Anti-Diabetic Pharmaceutical Market7.3.3 The Indian Anti-Diabetic Pharmaceutical Market8. The R&D Pipeline for Diabetes Treatments8.1 The Anti-Diabetic Drugs Pharmaceutical Pipeline8.2 The Human Insulins and Analogues Pipeline8.2.1 Technosphere Insulin (Mankind)8.2.2 VIAject/VIAdel (Biodel)8.2.3 CKD 401(Chong Kun Dang)8.2.4 BHT 3021/RG 7426 (Bayhill Therapeutics/Genentech)8.2.5 Nasulin/CPE-215 (CPEX Pharmaceuticals)8.2.6 Capsulin (Diabetology)8.2.7 ORMD 0801 (Oramed)8.2.8 TPM 02/Insulin (Phosphagenics)8.2.9 IN 105 (Biocon)8.2.10 NN 1250 (Novo Nordisk)8.2.11 NN 5401 (Novo Nordisk)8.2.12 SBS 1000 (SemBioSys)8.3 The Glitazone Anti-Diabetics Pipeline8.3.1 ACTOplus met XR (Takeda)8.3.2 Balaglitazone/DRF 2593 (Dr Reddys/Nordic Bioscience)8.3.3 MK 0431C (Merck & Co)8.3.4 MSDC 0160 (Metabolic Solutions Development)8.3.5 Lobeglitazone/CKD 501 (Chong Kun Dang)8.4 DPP-IV Inhibitor Anti-Diabetics Pipeline8.4.1 SYR 322 (Takeda)8.4.2 Alogliptin (Takeda)8.4.3 Linagliptin/BI 1356 BS (Boehringer Ingelheim)8.4.4 Dutogliptin/PHX 1149 (Phenomix)8.4.5 LC 15 0444 (LG Life Sciences)World Diabetes Market Analysis 2010-2025 Page 4/12
    • Find Industry reports, Company profilesReportLinker and Market Statistics8.4.6 Saxagliptin and Metformin Combination8.4.7 MK 0431C (Merck & Co)8.4.8 SK 0403 (Sanwa Kagaku/ Kowa/ Choongwae)8.4.9 Teneligliptin/MP 513 (Mitsubishi Tanabe Pharma)8.4.10 ALS 20426/AMG 222 (Amgen)8.4.11 Carmegliptin/R 1579 (Roche)8.4.12 KRP 104 (Kyorin)8.4.13 Melogliptin/GRC 8200 (Glenmark)8.4.14 SYR 472 (Takeda)8.4.15 TA 6666 (Mitsubishi Tanabe Pharma)8.5 Sulphonylurea and Biguanide Anti-Diabetics Pipeline8.5.1 NCT00660907/Dapagliflozin + Metformin Combination (AstraZeneca)8.5.2 Metformin XL (Flamel Technologies)8.5.3 Metcontrol (Generex Biotechnology)8.6 Alpha-glucosidase Inhibitor Anti-Diabetics Pipeline8.6.1 KMV 0207 (Kissei/Takeda)8.6.2 PharmaLinks Compounds (University of Strathclyde)8.7 Miscellaneous Class of Anti-Diabetic Drugs in the R&D Pipeline8.7.1 Byetta LAR/AC 2993 LAR (Amylin/Alkermes/Eli Lilly)8.7.2 Albiglutide/GSK 716155 (GlaxoSmithKline)8.7.3 Lixisenatide/ZP 10/AVE 0010 (sanofi-aventis)8.7.4 LY 2189265 (Eli Lilly)8.7.5 Taspoglutide/ BIM 51077 (Roche)8.7.6 ITCA 650 (Intarcia)8.7.7 Gosogliptin/PF 734200 (Pfizer)8 7.8 Semaglutide/NN 9535 (Novo Nordisk)8.7.9 Bromocriptine/Cycloset (VeroScience/ S2 Therapeutics)8.7.10 SF 1019/R-1818 (Argyll Biotechnologies)8.7.11 Arhalofenate/MBX 102 (Metabolex and Ortho-McNeil)8.7.12 Canagliflozin/TA 7284 (Mitsubishi Tanabe Pharma/ Johnson & Johnson)8.7.13 Dapagliflozin (Bristol-Myers Squibb)8.7.14 DiaPep277 (Andromeda/ DeveloGen)8.7.15 Mirabegron/YM 178 (Astellas)8.7.16 Otelixizumab/TRX 4/ChAglyCD3 (GlaxoSmithKline/Tolerx/BTG)8.7.17 Teplizumab/MGA 031 (MacroGenics/Eli Lilly)8.7.18 DIAMYD/GAD65 (Diamyd Medical)9. Expert Views from Key Opinion Leaders9.1 Prof. R. Keith Campbell, Pharm.B., MBA, CDE Distinguished Professor in Diabetes Care, Department of Pharmacotherapy,College of Pharmacy, Washington State University, WA, US9.1.1 Key Unmet Needs9.1.2 About Research and Development9.1.3 Problems with the Current Use of Anti-Diabetic Treatments9.1.4 Challenges in the Development of Anti-Diabetic Drugs9.1.5 Complexities Involved in Developing New Anti-Diabetic Drugs9.1.6 Technologies and Strategies for Discovery of New Anti-Diabetic Agents9.1.7 Growth Opportunities in Diabetes Market9.1.8 Challenges Facing the Diabetes Pharmaceutical Industry9.1.9 Main Regions Offering Growth Potential Worldwide9.1.10 Pipeline Developments from a Physicians PerspectiveWorld Diabetes Market Analysis 2010-2025 Page 5/12
    • Find Industry reports, Company profilesReportLinker and Market Statistics9.1.11 Prospects of Replacing Current Drugs and Treatments9.2 Interview with Dr Fred Levine, M.D., Ph.D. Professor, Burnham Institute for Medical Research; Director, Sanford Childrens HealthResearch Center, La Jolla, California, US9.2.1 On Alternative Delivery Methods9.2.2 On Cardiovascular Problems Associated with Oral Anti-Diabetics9.2.3 On Obesity and Diabetes9.2.4 On Byetta9.2.5 On Stem Cell Therapy/Cure9.3 Interview with Björn Tyrberg, PhD., Associate Professor, Metabolic Signaling & Disease, Diabetes and Obesity Research Center,Burnham Institute for Medical Research, La Jolla, CA, US9.3.1 On Diet and Diabetes9.3.2 On The Link Between Obesity and Diabetes9.3.3 On Byetta and Liraglutide10. Conclusions: Diabetes is a Growth Market with Significant Opportunities10.1 Diabetes Increasing Worldwide: 2-14% Prevalence Rate10.2 World Diabetes Market: A Growing Opportunity10.3 Oral Anti-Diabetics Sales vs. Insulins SalesList of TablesTable 2.1 Diabetes Numbers (in Millions), by WHO Region, 2000 & 2030Table 2.2 Secondary Costs of Diabetes in the US, 2007Table 2.3 Total Costs of Diabetes to Africa: $4.2 Billion, 2007Table 2.4 Diabetes World Market Sales, 2009Table 2.5 Insulin Types by Onset Rate, 2010Table 2.6 Alternative Delivery Methods in the R&D Pipeline by Type and Development Stage, 2010Table 2.7 Anti-Diabetic Drugs by Class, 2010Table 3.1 Diabetes Pharmaceutical Therapeutic Category Market Shares, 2009Table 3.2 Top Twenty Diabetes Pharmaceutical Brands, 2009Table 3.3 World Diabetes Pharmaceutical Market Sales Forecast, 2010-2016Table 3.4 World Diabetes Pharmaceutical Market Sales Forecast, 2017-2025Table 3.5 Diabetes Pharmaceutical Therapeutic Category Sales Forecasts, 2010-2016Table 3.6 Diabetes Pharmaceutical Therapeutic Category Sales Forecasts, 2017-2025Table 4.1 Lantus Sales Forecast, 2010-2016Table 4.2 Lantus Sales Forecast, 2017-2025Table 4.3 Novorapid Sales Forecast, 2010-2016Table 4.4 Novorapid Sales Forecast, 2017-2025Table 4.5 Humalog Sales Forecast, 2010-2016Table 4.6 Humalog Sales Forecast, 2017-2025Table 4.7 Novomix Sales Forecast, 2010-2016Table 4.8 Novomix Sales Forecast, 2017-2025Table 4.9 Levemir Sales Forecast, 2010-2016Table 4.10 Levemir Sales Forecast, 2017-2025Table 4.11 Actraphane HM Sales Forecast, 2010-2016Table 4.12 Actraphane HM Sales Forecast, 2017-2025Table 5.1 Actos Sales Forecast, 2010-2016Table 5.2 Actos Sales Forecast, 2017-2025Table 5.3 Avandia Sales Forecast, 2010-2016Table 5.4 Avandia Sales Forecast, 2017-2025World Diabetes Market Analysis 2010-2025 Page 6/12
    • Find Industry reports, Company profilesReportLinker and Market StatisticsTable 5.5 Avandamet Sales Forecast, 2010-2016Table 5.6 Avandamet Sales Forecast, 2017-2025Table 5.7 Junuvia Sales Forecast, 2010-2016Table 5.8 Junuvia Sales Forecast, 2017-2025Table 5.9 Byetta Sales Forecast, 2010-2016Table 5.10 Byetta Sales Forecast, 2017-2025Table 6.1 SWOT Analysis for World Diabetes Market: Strengths & Weaknesses, 2010-2025Table 6.2 SWOT Analysis for World Diabetes Market: Opportunities & Threats, 2010-2025Table 6.3 Recent FDA Guidance on the Cardiovascular Risk of Diabetes DrugsTable 7.1 Leading Diabetes Drugs: Country Markets, 2009Table 7.2 Leading Anti-Diabetic Drugs: Country Market Sales Forecasts, 2010-2016Table 7.3 Leading Anti-Diabetic Drugs: Country Market Sales Forecasts, 2017-2025Table 8.1 Key Drugs in the Human Insulins and Analogues R&D Pipeline, 2009Table 8.2 Key Drugs in the Glitazone Anti-Diabetics R&D Pipeline, 2009Table 8.3 Key Drugs in the DPP-IV Inhibitor Anti-Diabetics R&D Pipeline, 2009Table 8.4 Key Drugs in the Sulphonylurea and Biguanide Anti-Diabetics R&D Pipeline, 2009Table 8.5 Key Drugs in the Alpha-Glucosidase Inhibitor Anti-Diabetics R&D Pipeline, 2009Table 8.6 Key Drugs in the Miscellaneous Class R&D Pipeline, 2009List of FiguresFigure 2.1 Rise in Diabetes Cases (in Millions), by WHO Region, 2000 & 2030Figure 2.2 Secondary (Non-Medical) Costs of Diabetes in the US, 2007Figure 2.3 Secondary Costs of Diabetes in Africa, 2007Figure 3.1 Diabetes Pharmaceutical Therapeutic Category Market Shares, 2009Figure 3.2 World Diabetes Pharmaceutical Market Sales Forecasts, 2010-2016Figure 3.3 World Diabetes Pharmaceutical Market Sales Forecasts, 2017-2025Figure 3.4 Diabetes Pharmaceutical Therapeutic Category Market Shares, 2009Figure 3.5 Diabetes Pharmaceutical Therapeutic Category Market Shares, 2015Figure 3.6 Diabetes Pharmaceutical Therapeutic Category Market Shares, 2020Figure 3.7 Diabetes Pharmaceutical Therapeutic Category Market Shares, 2025Figure 3.8 Diabetes Pharmaceutical Therapeutic Category Sales Forecasts, 2010-2025Figure 4.1 Lantus Sales Forecast, 2010-2025Figure 4.2 Novorapid Sales Forecast, 2010-2025Figure 4.3 Humalog Sales Forecast, 2010-2025Figure 4.4 Novomix Sales Forecast, 2010-2025Figure 4.5 Levemir Sales Forecast, 2010-2025Figure 4.6 Actraphane HM Sales Forecast, 2010-2025Figure 5.1 Actos HM Sales Forecast, 2010-2025Figure 5.2 Avandia Sales Forecast, 2010-2025Figure 5.3 Avandamet Sales Forecast, 2010-2025Figure 5.4 Junuvia Sales Forecast, 2010-2025Figure 5.5 Byetta Sales Forecast, 2010-2025Figure 6.1 Global Population Aged Over 65 Years, 2010-2025Figure 6.2 Population Aged 65 Years or Over in Major Anti-Diabetic Pharmaceutical Country Markets, 2009 and 2025Figure 6.3 Prevalence of Diabetes Worldwide in Major Anti-Diabetic Pharmaceutical Country Markets, 2000 and 2030Figure 6.4 Global Prevalence of Diabetes and Diabetic Retinopathy, 2007 and 2030Figure 7.1 Leading Anti-Diabetic Drugs: Country Market Shares, 2009Figure 7.2 Leading Anti-Diabetic Drugs: Country Market Shares, 2015Figure 7.3 Leading Anti-Diabetic Drugs: Country Market Shares, 2020World Diabetes Market Analysis 2010-2025 Page 7/12
    • Find Industry reports, Company profilesReportLinker and Market StatisticsFigure 7.4 Leading Anti-Diabetic Drugs: Country Market Shares, 2025Figure 7.5 US and Japanese Anti-Diabetic Drugs: Market Sales Forecasts, 2010-2025Figure 7.6 European, Chinese, Indian and Brazilian Anti-Diabetic Drugs: Market Sales Forecasts, 2010-2025Companies ListedAbbott Laboratories Ltd.ActivXAlkermes, Inc.Altea Therapeutics Corp.American Diabetes Association (ADA)Amgen Inc.Amylin Pharmaceuticals, Inc.Andromeda Biotech (a subsidiary of Clal Biotechnology Industries)Astellas Pharma Inc.AstraZeneca plc.Argyll Biotechnologies, LLCAxcess Ltd.Battelle Medical Device SolutionsBaxter International Inc.Bayhill Therapeutics Inc.Biocon Ltd.Biodel Inc.Boehringer Ingelheim GmbHBristol-Myers Squibb PharmaceuticalsBTG plcCenter for Biotechnology and Genomic Medicine, Medical College of Georgia, USChiesi Ltd.Chong Kun Dang Pharmaceutical Corp.Choongwae Pharma Corp.College of Pharmacy, Washington State University, WA, USCPEX Pharmaceuticals, Inc.DeveloGen AGDiabetology Ltd.Diamyd Medical ABDiabetes and Obesity Research Center, Burnham Institute for Medical Research, La Jolla, CA, USDPT Laboratories Ltd.Dong Sung Industrial Co., Ltd.Dr. Reddys Laboratories Ltd.Eli Lilly and Company LimitedEuropean Medicines Agency (EMEA)European Patent ConventionEmisphere Technologies, Inc.Ergo Sciences Inc.Forest Laboratories, Inc.Flamel Technologies, Inc.Food and Drug Administration (FDA) [US]Garvan Institute of Medical Research, Sydney, AustraliaGalenix Pharma and Galenix Inc.World Diabetes Market Analysis 2010-2025 Page 8/12
    • Find Industry reports, Company profilesReportLinker and Market StatisticsGenentech Inc.Generex Biotechnology Corp.GlaxoSmithKline plc (GSK)Glenmark Pharmaceuticals Ltd.Human Genome Sciences, Inc.Intarcia Therapeutics, Inc.International Diabetes Federation (IDF)Immunosyn CorporationIpsen Ltd.Johnson & Johnson Inc.Kissei Pharmaceutical Co, Ltd.Kowa Company Ltd.KYORIN Pharmaceutical Co., Ltd.LG Life Sciences Ltd.Lifescan UK (Ortho Clinical Diagnostics Ltd.)MacroGenicsMannKind Corp.Merck & Co., Inc.Metabolic Solutions Development Co.Metabolex Inc.Mitsubishi Tanabe Pharma Corp.Nordic Bioscience A/S.Novartis AG.Novo Nordisk A/S.Oramed Pharmaceuticals Inc.Ortho-McNeil-Janssen Pharmaceuticals, IncPDL BioPharma Inc.Pfizer Inc.PharmaLinksPhenomix Corp.Phosphagenics Ltd.Proxima Concepts Ltd.Qdose Ltd.Roche Holdings AG.Royal Adelaide Hospital, Adelaide, AustraliaS2 Therapeutics Inc.Sanford Childrens Health Research Center, La Jolla, California, USsanofi-aventisSanford Childrens Health Research Center, La Jolla, California, USSanwa Kagaku Kenkyusho Co., Ltd.SemBioSys Genetics Inc.Servier LaboratoriesTakeda Pharmaceuticals Co. Ltd.Teijin Pharma LimitedTeva Pharmaceutical Industries Ltd.Tolerance TherapeuticsTolerx, Inc.The National Diabetes Information ClearinghouseUniversity of California at Los Angeles (UCLA), USUniversity of Strathclyde, Glasgow, UKWorld Diabetes Market Analysis 2010-2025 Page 9/12
    • Find Industry reports, Company profilesReportLinker and Market StatisticsVeroScience LLC.Washington State University, WA, USWatson Pharmaceuticals, Inc.World Diabetes Congress of the International Diabetic FederationWorld Health Organisation (WHO)Yeda Research and Development Company Ltd.Ypsomed Holding AG.Zealand Pharma A/SWorld Diabetes Market Analysis 2010-2025 Page 10/12
    • Find Industry reports, Company profilesReportLinker and Market Statistics Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. World Diabetes Market Analysis 2010-2025 Product Formats Please select the product formats and the quantity you require. 1 User License--USD 2 417.21 Quantity: _____ Department License--USD 4 834.42 Quantity: _____ Site License--USD 8 046.71 Quantity: _____ Corporate License--USD 11 265.95 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________World Diabetes Market Analysis 2010-2025 Page 11/12
    • Find Industry reports, Company profilesReportLinker and Market Statistics Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93World Diabetes Market Analysis 2010-2025 Page 12/12